Showing results (311-320 of 339) with videos related to
Sort By:
Pageof 34
Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy|August 13, 2022
Central nervous system mucormycosis in a patient with hematological malignancy: A case report and review of the literatureShuichi Shirane, Yuho Najima, Kazuaki Fukushima, et al.Acta Haematologica|February 7, 2019
Efficacy and Safety of a Weekly Cyclophosphamide-Bortezomib-Dexamethasone Regimen as Induction Therapy Prior to Autologous Stem Cell Transplantation in Japanese Patients with Newly Diagnosed Multiple Myeloma: A Phase 2 Multicenter TrialKeisuke Tanaka, Shigeo Toyota, Megumi Akiyama, et al.Annals of Hematology|January 11, 2021
A multicenter phase II study of intrabone single-unit cord blood transplantation without antithymocyte globulinTetsuya Nishida, Takeshi Kobayashi, Masashi Sawa, et al.Journal of Clinical and Experimental Hematopathology : JCEH|June 26, 2024
Early failure is still a poor prognostic factor in patients with relapsed or refractory large B-cell lymphoma in the era of CAR T-cell therapyYu Yagi, Yusuke Kanemasa, Yuki Sasaki, et al.Scientific Reports|December 18, 2020
T-cell receptor repertoire of cytomegalovirus-specific cytotoxic T-cells after allogeneic stem cell transplantationTakashi Toya, Ayumi Taguchi, Kazutaka Kitaura, et al.American Journal of Hematology|October 29, 2025
Platelet Recovery and Its Impact on Outcomes After Allogeneic Hematopoietic Stem Cell Transplantation: A Japanese Nationwide Retrospective StudyNaoki Kurita, Kazushi Maruo, Fumihiko Kimura, et al.[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology|August 4, 2022
[Klinefelter's syndrome diagnosed at the onset of acute myeloid leukemia with inv (16) following treatment for germ cell tumor]Kisa Tanabe, Yuho Najima, Takuhiko Inokuchi, et al.Leukemia Research|April 30, 2025
Pre-transplant blinatumomab and/or inotuzumab ozogamicin therapy for relapsed/refractory acute lymphoblastic and B/myeloid mixed phenotype acute leukemia in adultsKaori Kondo, Yuho Najima, Daichi Sadato, et al.Cancer|March 25, 2026
Final clinical data of a phase 1 dose-escalation study of WVT078, a BCMA×CD3 bispecific antibody, alone and in combination with γ-secretase inhibitor WHG626 in patients with relapsed and/or refractory multiple myelomaFredrik Schjesvold, Andrew Spencer, Yael C Cohen, et al.[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology|May 13, 2026
[Clinical outcomes of idecabtagene vicleucel therapy for relapsed/refractory multiple myeloma: a single-center retrospective analysis]Kairi Kojo, Yuho Najima, Kyoko Haraguchi, et al.Pageof 34